Prof Richard Scolyer AO honoured with ASDP Founders’ Award
This is the highest award from the American Society of Dermatopathology, and recognises Prof Scolyer's significant contribution to the field of #dermatopathology.
This is the highest award from the American Society of Dermatopathology, and recognises Prof Scolyer's significant contribution to the field of #dermatopathology.
Read more about the five MIA researchers named on the Clarivate list of Highly Cited Researchers 2022.
Read more about the Cancer Institute NSW Awards and the highly cited immunotherapy publication.
Tailoring skin checks based on personal risk, the impact of adjuvant and neo-adjuvant therapies, and the latest in personalised immunotherapy for advanced patients are amongst a plethora of research advances.
Sun Safe Sport initiative and modernised awareness campaign critical to preventing melanoma which claims more lives than our annual road toll.
New clinical tool developed by Melanoma Institute Australia hailed a breakthrough in personalising treatment for all cancer patients.
Prof Georgina Long and Prof Richard Scolyer, cycled from Albury to Wagga on Day 1 of Riverina Melanoma Ride.
Melanoma March 2022 is aiming to raise $1 million for a world-first clinical trial of a Personalised Immunotherapy Platform which could transform melanoma treatment.
A landmark report provides status of melanoma in Australia, and the the roadmap to achieve zero deaths from melanoma this decade.
In what is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy, a new study has revealed that drug treatment before surgery is effective in preventing deadly spread of the disease.